3 MU, three times a week for 6 weeks, alternated with metothrexate and 6-mercaptopurine every 6 weeks, continuously administered for 1 year, as described elsewhere. 4 Afterwards, the patient was treated with a-IFN alone with the same schedule (6 weeks on, 6 weeks off) without interruption until morphological CR was maintained. 4 In March 2000, a second hematological relapse was documented. The patient was then enrolled in an international phase II study and treated with imatinib mesylate (formerly STI571; Novartis Pharma, Basel, Switzerland) at a daily dose of 600 mg, 5 obtaining the third hematological CR (April 2000), with persistence, however, of detectable BCR-ABL1 transcripts on bone marrow sample. In October 2000, the third hematological relapse occurred. As the patient was not anymore suitable for conventional CHT, we administered a combination of a-IFN (1 MU three times a week s.c.) and oral imatinib mesylate (600 mg daily), The patient obtained a fourth complete morphological remission in November 2000. The effects of such combination were monitored by both nested RT-PCR and real-time quantitative PCR performed on bone marrow samples. Noteworthy, PCR analyses documented a molecular CR lasting for 75 consecutive months ( Figure 1) . 3 Importantly, although other authors independently confirmed the efficacy of this combination in the treatment of Ph þ ALL, 6 we observed, in this case, the longest CR so far reported with such schedule. 3 In June 2007, the patient experienced a fourth relapse. Thus, the imatinib/a-IFN therapy was suspended and dasatinib (formerly BMS 354825; Bristol-Mayer-Squibb, New York, NY, USA), a second generation oral, dual inhibitor of BCR-ABL and SRC family kinases was given at the dose of 70 mg b.i.d., basing on its documented efficacy in imatinib-resistant cases. 7 However, after obtaining a brief hematological CR with only mild decrease of the BCR-ABL1 transcript, the patient suffered from a fifth documented relapse in November 2007. Relevantly, no BCR-ABL1 point mutations assessed by conventional sequencing were documented at this time. Bearing in mind the previous efficacy of a-IFN combined with imatinib, after a short cytoreductive therapy consisting of four doses of vincristine (2 mg, days 1, 8, 15, 22) associated with 6-methylprednisolone (40 mg/day for 28 days), the patient received dasatinib (100 mg/ day) plus a-IFN (0.5 MU, three times a week) from January 2008. We decided to administer to the patient a-IFN 0.5 MU, three times a week instead of 1 MU three times a week due to the heavily pretreated status of the patient and due to the higher potency of dasatinib with respect to imatinib. The combined treatment was indeed well tolerated, with only minor side effects (grade I-II skin rash), and dose reduction was not required at any time for any of the two drugs. Focusing on hematological toxicity, the patient did not present any grade IV toxicity. A transient grade III anemia was observed from the third month of the combined therapy. We did not observe any leucopenia or thrombocytopenia of any grade at any point during the combined treatment. Furthermore, most importantly, the treatment was quite effective by inducing, in particular, a dramatic reduction of the BCR-ABL1 transcripts, and the patient achieved a second molecular CR. At the time of writing, 13 months after receiving the first dose of the combination dasatinib/a-IFN, the patient is alive and in continuous second molecular CR (nested RT-PCR performed on bone marrow).
To the best of our knowledge, this is the first evidence of efficacy of the combination of dasatinib and a-IFN in a Ph þ ALL patient resistant to both imatinib and dasatinib as single agents. In our opinion, this is an emblematic case, underlying the possible additive/synergistic effect of a-IFN given in combination with other antileukemic agents, including TKIs in Ph þ ALL. Notably, in particular, the addition of a-IFN was shown to be effective in patients with sub-optimal response to imatinib, 3, 6 or even possibly curative in Ph þ ALL patients receiving CHT and ASCT. 4, 8 In conclusion, although new regimens combining different TKIs or TKIs and other agents are under evaluation, we think that the association of dasatinib and a-IFN might be reasonable for patients with sub-optimal response to dasatinib and not suitable for other approaches.
